
Carlos Henrique dos Anjos, MD, discussed how drug access and cost influenced HER2-positive breast cancer treatment choices in Brazil.

Carlos Henrique dos Anjos, MD, discussed how drug access and cost influenced HER2-positive breast cancer treatment choices in Brazil.